JP2017503756A5 - - Google Patents

Download PDF

Info

Publication number
JP2017503756A5
JP2017503756A5 JP2016533116A JP2016533116A JP2017503756A5 JP 2017503756 A5 JP2017503756 A5 JP 2017503756A5 JP 2016533116 A JP2016533116 A JP 2016533116A JP 2016533116 A JP2016533116 A JP 2016533116A JP 2017503756 A5 JP2017503756 A5 JP 2017503756A5
Authority
JP
Japan
Prior art keywords
muscle activity
treatment
deuterium
abnormal muscle
structural formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016533116A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017503756A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/066740 external-priority patent/WO2015077520A1/en
Publication of JP2017503756A publication Critical patent/JP2017503756A/ja
Publication of JP2017503756A5 publication Critical patent/JP2017503756A5/ja
Pending legal-status Critical Current

Links

JP2016533116A 2013-11-22 2014-11-21 異常な筋活動を処置する方法 Pending JP2017503756A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907675P 2013-11-22 2013-11-22
US61/907,675 2013-11-22
PCT/US2014/066740 WO2015077520A1 (en) 2013-11-22 2014-11-21 Methods of treating abnormal muscular activity

Publications (2)

Publication Number Publication Date
JP2017503756A JP2017503756A (ja) 2017-02-02
JP2017503756A5 true JP2017503756A5 (enExample) 2018-01-11

Family

ID=53180159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016533116A Pending JP2017503756A (ja) 2013-11-22 2014-11-21 異常な筋活動を処置する方法

Country Status (8)

Country Link
US (1) US20160303110A1 (enExample)
EP (1) EP3071565A4 (enExample)
JP (1) JP2017503756A (enExample)
CA (1) CA2930167A1 (enExample)
HK (1) HK1224294A1 (enExample)
IL (1) IL245538A0 (enExample)
MX (1) MX2016006622A (enExample)
WO (1) WO2015077520A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
JP6362601B2 (ja) 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態
AU2014357518A1 (en) 2013-12-03 2016-06-09 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
EP2918266A1 (en) * 2014-03-11 2015-09-16 CDRD Berolina AB Composition comprising a dopamine agonist and an L-DOPA derivative for treating Parkinson's disease
PL3265085T3 (pl) 2015-03-06 2022-11-07 Auspex Pharmaceuticals, Inc. Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
US10786202B2 (en) 2016-09-28 2020-09-29 International Business Machines Corporation Quantifying grip strength and characterizing movement idioms

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7367953B2 (en) * 2003-11-26 2008-05-06 Ge Medical Systems Global Technology Company Method and system for determining a period of interest using multiple inputs
BRPI0708071A8 (pt) * 2006-02-17 2017-12-26 Birds Pharma Gmbh Berolina Innovative Res & Development Services Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos
ES2525932T3 (es) * 2006-05-02 2015-01-02 The Trustees Of The University Of Pennsylvania Derivados de dihidrotetrabenazina radiomarcados y su uso como agentes de imagenología
US8008500B2 (en) * 2007-06-08 2011-08-30 General Electric Company Intermediates useful for making tetrabenazine compounds
EP2674104B1 (en) * 2008-06-12 2015-05-27 Amygdala Pty Ltd Detection of hypokinetic and/or hyperkinetic states
PL2318035T3 (pl) * 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
NZ591615A (en) * 2008-09-18 2012-07-27 Auspex Pharmaceuticals Inc Benzoquinoline inhibitors of vesicular monoamine transporter 2
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
US20120003330A1 (en) * 2010-06-01 2012-01-05 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
US9676810B2 (en) * 2010-07-08 2017-06-13 The Brigham And Women's Hospital, Inc. Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules
US9901564B2 (en) * 2012-03-23 2018-02-27 Cardero Therapeutics, Inc. Compounds and compositions for the treatment of muscular disorders

Similar Documents

Publication Publication Date Title
EP4663637A3 (en) Novel deuterium substituted positron emission tomography (pet) imaging agents and their pharmacological application
NZ721645A (en) Compounds for use as gpr120 agonists
BRPI0821994B8 (pt) composto ou um enantiômero, um diasteroisômero ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
JP2012526791A5 (enExample)
RU2010145459A (ru) Ингибиторы активности протеинтирозинкиназы
EA201590520A1 (ru) Фармацевтическая композиция с покрытием, содержащая регорафениб
CL2013001558A1 (es) El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico.
FI3738434T3 (fi) Välituotteita substituoitujen bentsaldehydiyhdisteiden saamiseksi ja menetelmiä niiden käyttöön kudosten hapetuksen lisäämiseksi
HRP20191617T1 (hr) Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
EP2723359A4 (en) METHOD FOR THE TREATMENT OF DIABETES WITH THE HELP OF DELAYED RELEASED FORMULATIONS FROM GLP-1 RECEPTOR AGONISTS
JP2015513557A5 (enExample)
MY189770A (en) Biaryl derivative as gpr120 agonists
JP2017506627A5 (enExample)
BR112014005389A8 (pt) Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal
BR112022008786A2 (pt) Composto, composição, uso do composto ou da composição, e, método para tratar ou prevenir uma complicação diabética, doença relacionada à neuroinflamação ou aterosclerose
WO2016012965A3 (en) Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof
MX377202B (es) Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo.
RU2008139315A (ru) Избирательные андрогенные рецепторные модуляторы
MX2016007056A (es) Metodos para preparar compuestos de benzoquinolina.
EA201071099A1 (ru) СОЛЕВЫЕ ФОРМЫ ИНГИБИТОРА mTOR
EA201590735A1 (ru) 2-фенил-5-гетероциклил-тетрагидро-2h-пиран-3-аминовые соединения для применения в лечении диабета и связанных с ним расстройств
JP2014062126A5 (enExample)
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
BR112017020484A2 (pt) método para a fabricação de novo composto contendo nitrogênio ou sal do mesmo e intermediário de fabricação do novo composto contendo nitrogênio ou sal do mesmo